Abstract:In recent years, engineering T cell therapy has made great progress in tumor immunotherapy, which mainly includes T-cell receptor-engineered T cell（TCR-T） therapy and chimeric antigen receptor T cell（CAR-T） therapy. Due to their structure difference, TCR-T and CAR-T cells show different characteristics in signal activation and antigen recognition. CAR has scFv derived from antibody, containing CD3ζ and costimulatory domain（s）, making engineered CAR able to recognize specific tumor associated antigens. Therefore, CAR has an ability to bind unprocessed tumor surface antigens without MHC processing, while TCR engages with both tumor intracellular and surface antigens embedded in MHC. While CAR-T cell therapy has demonstrated a significant clinical effect against malignant blood tumors, TCR-T cell therapies have been tested in hematological and solid tumors. Even though clinical results are encouraging for both approaches, several major challenges have been identified, including: target antigen selection such as less tumor toxicity and antigen escape, T cell homing to the tumor, T cell infiltration into the tumor, T cell persistence, and local immunosuppression in the tumor microenvironment. Synthetic biology technologies have enabled flexible reprogramming of engineered T cells to overcome the aforementioned limitations, bringing new opportunities for improving their safety and effectiveness, but the choice of a suitable target antigen is still a key for success. Moreover, improved preclinical TCR/CAR screening is likely to enhance the safety of engineered T cell therapies, and additional T cell engineering to further enhance engineered T cells at various levels has generated promising results, including:（1） modulation of affinity,（2） safety control elements, and（3） targeting TME components. Future developments will likely harness combinatorial strategies to overcome challenges posed by the tumors. In this article, we address structure and signal activation, target selection, affinity optimization, safety modification and gene editing strategies for engineered T cells, and also review the potential synthetic biological approaches and latest progress of engineered T cell therapy in the application of tumor immunotherapy.

Synthetic biology and engineered T cell therapy

Genetically engineered T cells for cancer immunotherapy

Exploiting T cell signaling to optimize engineered T cell therapies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Targeting cancers through TCR-peptide/MHC interactions

Improving the efficacy and safety of engineered T cell therapy for cancer.

Synthetic immunology: T-cell engineering and adoptive immunotherapy

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Engineering Chimeric Antigen Receptor-T Cells for Cancer Treatment

Synthetic Cells and Molecules in Cellular Immunotherapy

Emerging Strategies in TCR-Engineered T Cells

CAR T cells: Building on the CD19 paradigm

Breakthroughs in synthetic controlling strategies for precision in CAR-T therapy

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

[Cell therapy's poster child: Chimeric antigen receptor T cell therapy]

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Engineered T Cell Receptor for Cancer Immunotherapy

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility